S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

$39.95
-0.20 (-0.50%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$39.47
$41.06
50-Day Range
$33.32
$40.86
52-Week Range
$29.85
$59.40
Volume
732,900 shs
Average Volume
1.18 million shs
Market Capitalization
$5.28 billion
P/E Ratio
21.25
Dividend Yield
N/A
Price Target
$52.73

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
32.0% Upside
$52.73 Price Target
Short Interest
Bearish
5.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
1.40mentions of Halozyme Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$756,200 Sold Last Quarter
Proj. Earnings Growth
45.63%
From $2.52 to $3.67 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

20th out of 942 stocks

Biological Products, Except Diagnostic Industry

2nd out of 157 stocks


HALO stock logo

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

HALO Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Halozyme Therapeutics Inc HALO
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Halozyme Therapeutics, Inc. Q3 Profit Increases, beats estimates
Halozyme Therapeutics Announces Thirteenth License Partner For ENHANZE
Halozyme Therapeutics earnings: here's what Wall Street expects
12 Cheap Biotech Stocks Smart Investors Are Piling Into
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
393
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$52.73
High Stock Price Target
$66.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+32.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$202.13 million
Pretax Margin
40.72%

Debt

Sales & Book Value

Annual Sales
$660.12 million
Cash Flow
$2.58 per share
Book Value
$1.26 per share

Miscellaneous

Free Float
128,928,000
Market Cap
$5.28 billion
Optionable
Optionable
Beta
1.25

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 60)
    M.R.C.P., President, CEO & Director
    Comp: $1.45M
  • Ms. Nicole LaBrosseMs. Nicole LaBrosse (Age 40)
    Senior VP & CFO
    Comp: $727.04k
  • Dr. Michael J. LaBarre Ph.D. (Age 59)
    Senior VP & Chief Technical Officer
    Comp: $723.24k
  • Mr. Mark Snyder Esq.
    Chief Legal Officer
  • Ms. Cortney Caudill M.B.A.
    Chief Operations Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corporate Communications
  • Ms. Amy Marinne Fox
    Chief Human Resources Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Dr. Christopher Bryant Ph.D. (Age 62)
    Chief Manufacturing Officer & Head of Technical Operations
  • Ms. Kristin Schwartzbauer
    Head of Quality














HALO Stock Analysis - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price target for 2024?

11 equities research analysts have issued twelve-month target prices for Halozyme Therapeutics' shares. Their HALO share price targets range from $42.00 to $66.00. On average, they predict the company's stock price to reach $52.73 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 on January 1st, 2023. Since then, HALO shares have decreased by 29.8% and is now trading at $39.95.
View the best growth stocks for 2023 here
.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,970,000 shares, an increase of 5.9% from the October 31st total of 6,580,000 shares. Based on an average trading volume of 875,400 shares, the short-interest ratio is presently 8.0 days. Approximately 5.3% of the shares of the company are short sold.
View Halozyme Therapeutics' Short Interest
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. The biopharmaceutical company earned $216.03 million during the quarter, compared to the consensus estimate of $219.47 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 190.74% and a net margin of 32.52%.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY23 earnings guidance on Monday, November, 6th. The company provided EPS guidance of $2.70-$2.80 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $825-$845 million, compared to the consensus revenue estimate of $830.22 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.85%), Northern Trust Corp (1.52%), Charles Schwab Investment Management Inc. (1.29%), Bank of New York Mellon Corp (0.99%), Allspring Global Investments Holdings LLC (0.67%) and Kennedy Capital Management LLC (0.49%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
This page (NASDAQ:HALO) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -